Study details
Enrolling now
Fecal Microbiota Transplantation for Cancer-Related Diarrhea
M.D. Anderson Cancer Center
NCT IDNCT04038619ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
40
Study length
about 4.9 years
Ages
18+
Locations
1 site in TX
About this study
This trial is testing if fecal microbiota transplantation can help treat diarrhea or colitis caused by certain cancer medications in patients with genitourinary cancers. The treatment involves transplanting healthy bacteria from another person's stool into the patient's gut.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Loperamide
- 2.Undergo Fecal Microbiota Transplantation
PhasePhase 1
DrugLoperamide
Primary goalIncidence of fecal microbiota transplantation (FMT)-related adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
loperamide (Opioid receptor agonist in gut; slows intestinal movement)
Endpoints
Primary: Incidence of fecal microbiota transplantation (FMT)-related adverse events
Body systems
Oncology, Gastroenterology